These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 14506750)

  • 21. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
    Leung S; Miyake H; Zellweger T; Tolcher A; Gleave ME
    Int J Cancer; 2001 Mar; 91(6):846-50. PubMed ID: 11275990
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel.
    Kolfschoten GM; Hulscher TM; Duyndam MC; Pinedo HM; Boven E
    Biochem Pharmacol; 2002 Feb; 63(4):733-43. PubMed ID: 11992642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
    Mimeault M; Johansson SL; Vankatraman G; Moore E; Henichart JP; Depreux P; Lin MF; Batra SK
    Mol Cancer Ther; 2007 Mar; 6(3):967-78. PubMed ID: 17363490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
    Ogura T; Tanaka Y; Tamaki H; Harada M
    Int J Oncol; 2016 Jun; 48(6):2330-8. PubMed ID: 27082738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells.
    Gomez LA; de Las Pozas A; Perez-Stable C
    Mol Cancer Ther; 2006 May; 5(5):1216-26. PubMed ID: 16731754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines.
    Karaca B; Degirmenci M; Ozveren A; Atmaca H; Bozkurt E; Karabulut B; Sanli UA; Uslu R
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1273-80. PubMed ID: 25925002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased p21/WAF-1 and p53 protein levels following sequential three drug combination regimen of fludarabine, cytarabine and docetaxel induces apoptosis in human leukemia cells.
    Avramis VI; Nandy P; Kwock R; Solorzano MM; Mukherjee SK; Danenberg P; Cohen LJ
    Anticancer Res; 1998; 18(4A):2327-38. PubMed ID: 9703875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple anticancer effects of blocking MEK-ERK signaling in hepatocellular carcinoma.
    Wiesenauer CA; Yip-Schneider MT; Wang Y; Schmidt CM
    J Am Coll Surg; 2004 Mar; 198(3):410-21. PubMed ID: 14992744
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Docetaxel cytotoxicity is enhanced by inhibition of the Raf/MEK/ERK signal transduction pathway.
    Navolanic PM; Lee JT; McCubrey JA
    Cancer Biol Ther; 2003; 2(6):677-8. PubMed ID: 14688475
    [No Abstract]   [Full Text] [Related]  

  • 30. Requirement of c-jun for testosterone-induced sensitization to N-(4-hydroxyphenyl)retinamide-induced apoptosis.
    Shimada K; Nakamura M; Ishida E; Kishi M; Konishi N
    Mol Carcinog; 2003 Mar; 36(3):115-22. PubMed ID: 12619033
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The molecular mechanism of sensitization to Fas-mediated apoptosis by 2-methoxyestradiol in PC3 prostate cancer cells.
    Shimada K; Nakamura M; Ishida E; Kishi M; Matsuyoshi S; Konishi N
    Mol Carcinog; 2004 Jan; 39(1):1-9. PubMed ID: 14694442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study.
    Williams JF; Muenchen HJ; Kamradt JM; Korenchuk S; Pienta KJ
    Prostate; 2000 Sep; 44(4):275-8. PubMed ID: 10951491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis.
    Baek JH; Jang JE; Kang CM; Chung HY; Kim ND; Kim KW
    Oncogene; 2000 Sep; 19(40):4621-31. PubMed ID: 11030151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The novel antimicrotubule agent cryptophycin 52 (LY355703) induces apoptosis via multiple pathways in human prostate cancer cells.
    Drew L; Fine RL; Do TN; Douglas GP; Petrylak DP
    Clin Cancer Res; 2002 Dec; 8(12):3922-32. PubMed ID: 12473608
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
    Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
    Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC-3.
    Muenchen HJ; Poncza PJ; Pienta KJ
    Urology; 2001 Feb; 57(2):366-70. PubMed ID: 11182366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer.
    Cassinelli G; Lanzi C; Supino R; Pratesi G; Zuco V; Laccabue D; Cuccuru G; Bombardelli E; Zunino F
    Clin Cancer Res; 2002 Aug; 8(8):2647-54. PubMed ID: 12171897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inactivation of the antiapoptotic phosphatidylinositol 3-kinase-Akt pathway by the combined treatment of taxol and mitogen-activated protein kinase kinase inhibition.
    MacKeigan JP; Taxman DJ; Hunter D; Earp HS; Graves LM; Ting JP
    Clin Cancer Res; 2002 Jul; 8(7):2091-9. PubMed ID: 12114408
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
    Krainer M; Tomek S; Elandt K; Horak P; Albrecht W; Eisenmenger M; Höltl W; Schramek P; Stackl W; Zielinski C; Reibenwein J
    J Urol; 2007 Jun; 177(6):2141-5; discussion 2145. PubMed ID: 17509302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells.
    Nehmé A; Varadarajan P; Sellakumar G; Gerhold M; Niedner H; Zhang Q; Lin X; Christen RD
    Br J Cancer; 2001 Jun; 84(11):1571-6. PubMed ID: 11384110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.